Current Report Filing (8-k)
November 17 2022 - 8:01AM
Edgar (US Regulatory)
0000849636
false
0000849636
2022-11-14
2022-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 14, 2022
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
1-16467 |
|
33-0303583 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S
Employer
Identification
No.) |
126
Valley Road, Suite C
Glen
Rock, New Jersey |
|
07452 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On November 14, 2022, RespireRx Pharmaceuticals Inc.
(the “Company”) entered into a letter of intent (“LOI”) with an Australia headquartered bespoke clinical
research organization (“CRO”) focused on cannabinoid and psychedelic clinical research. The LOI calls for a target
execution date for a definitive contract that is 30 days from the date of the LOI, at which time RespireRx will be required to make a
US$50,000 deposit to be applied to the final studies budget and credited against the first invoice under the definitive contract. Under
the definitive contract, the CRO is expected to provide full service CRO services, including regulatory, compliance, GMP (good
manufacturing practices) manufacturing services in addition to human pharmacokinetic and pivotal human efficacy and safety studies of
dronabinol for the treatment of obstructive sleep apnea.
The
press release dated November 17, 2022 announcing the LOI, which includes further details with respect to the LOI, is attached as Exhibit
99.1 to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
A
list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which follows, and is incorporated
herein by reference.
EXHIBIT
INDEX
*
Furnished herewith.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
November 17, 2022 |
RESPIRERX
PHARMACEUTICALS INC. |
| |
(Registrant) |
| |
|
| |
By: |
/s/
Jeff E. Margolis |
| |
|
Jeff
E. Margolis |
| |
|
SVP,
CFO, Secretary and Treasurer |
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Dec 2024 to Jan 2025
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jan 2024 to Jan 2025
